[(-)-(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy)phenoxymethyl]piperidine acetate | 72471-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [(-)-(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy)phenoxymethyl]piperidine acetate
• 英文别名: paroxetine acetate；acetic acid;(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
• CAS: 72471-80-8
• 化学式: C₂H₄O₂*C₁₉H₂₀FNO₃
• 分子量: 389.424
• InChiKey: RQBJOWKBGCDPOS-RVXRQPKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.42
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  77
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [(-)-(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy)phenoxymethyl]piperidine acetate 在 盐酸 、 水 作用下， 以 异丙醇 为溶剂， 反应 1.0h， 以91.8%的产率得到盐酸帕罗西汀
  参考文献：
  名称：

  EP1555262

  摘要：

  公开号：

文献信息

• Process for preparing (+)trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
  申请人：——

  公开号：US20040215020A1

  公开（公告）日：2004-10-28

  The present invention relates to a process for preparing (±)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX′) methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine. 1

  本发明涉及一种制备式(I)的(±)-反式-4-对氟苯基-3-羟甲基-1-甲基哌啶的过程。本发明还涉及式(IX)和(IX')的新中间体、制备该中间体的方法以及使用该化合物制备帕罗西汀和奥米诺西汀的方法。
• Process for producing paroxetine salts substantially free from organic solvents
  申请人：ASAHI GLASS COMPANY LIMITED

  公开号：US20030158416A1

  公开（公告）日：2003-08-21

  A paroxetine salt free from an organic solvent is produced by substantially and safely removing the organic solvents from paroxetine hydrochloride. A process for producing a paroxetine salt, which comprises neutralizing paroxetine hydrochloride containing an organic solvent into paroxetine, then forming a salt of paroxetine with an acid other than hydrochloric acid, and crystallizing the salt from an organic solvent.

  一种无有机溶剂的帕罗西汀盐可通过从帕罗西汀盐酸盐中安全而有效地去除有机溶剂来制备。一种制备帕罗西汀盐的方法包括将含有有机溶剂的帕罗西汀盐酸盐中和成帕罗西汀，然后用盐酸以外的酸形成帕罗西汀盐，并从有机溶剂中结晶出盐。
• Optimized procedures for the manufacture of paroxetine salts
  申请人：——

  公开号：US20030032809A1

  公开（公告）日：2003-02-13

  Described herein are methods for manufacturing amorphous paroxetine hydrochloride by mixing a carboxylic acid salt of paroxetine with hydrogen chloride and isolating the amorphous paroxetine hydrochloride. Also described herein are methods for manufacturing substantially pure paroxetine free base and methods for obtaining paroxetine salts such as paroxetine acetate, paroxetine trifluoroacetate, and paroxetine formate. Also described are methods for preparing paroxetine carbonate, paroxetine phosphate, paroxetine sulfate, and analogous salts thereof. The paroxetine salts may be formulated for the treatment of medical disorders as described.

  本文描述了制造非晶态盐酸帕罗西汀的方法，包括将帕罗西汀的羧酸盐与氯化氢混合并分离出非晶态盐酸帕罗西汀。还描述了制造基本纯净的帕罗西汀自由基的方法，以及获取帕罗西汀醋酸盐、帕罗西汀三氟乙酸盐和帕罗西汀甲酸盐的方法。还描述了制备帕罗西汀碳酸盐、帕罗西汀磷酸盐、帕罗西汀硫酸盐及其类似盐的方法。这些帕罗西汀盐可用于治疗医疗疾病。
• Novel compound
  申请人：SmithKline Beecham p.l.c.

  公开号：US20010023253A1

  公开（公告）日：2001-09-20

  Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

  本发明公开了吡啶化合物、其制备方法、包含它们的制药组合物以及它们在治疗中的用途。
• Paroxetine isethionate salt, process of preparation and use in the treatment of depression
  申请人：——

  公开号：US20040225128A1

  公开（公告）日：2004-11-11

  A salt derived from isethionic acid and paroxetine free base of formula (I) 1

  一种盐，由异硫酸和公式（I）中的帕罗西汀自由基衍生而来。